LPCN News and Press, Lipocine Inc. From 03/22/22

Shares of Lipocine Inc. (NASDAQ:LPCN) traded today at $1.75, eclipsing its 52-week high. This new high was reached on approximately average trading volume as 767,000 shares traded hands, while the average 30-day volume is approximately 722,000 shares. Lipocine Inc. (NASDAQ:LPCN) defies a...

Lipocine press release (NASDAQ:LPCN): FY GAAP EPS of -$0.01. Revenue of $16.1M. As of December 31, 2021, the company had $44.6 million of unrestricted cash, cash equivalents, and marketable investments, compared to $19.7 million of unrestricted cash, cash equivalents ...

Lipocine Announces Financial Results for the Year Ended December 31, 2021 PR Newswire SALT LAKE CITY , March 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today ...

Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH PR Newswire SALT LAKE CITY , March 1, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today ...

Lipocine (LPCN) shares are trading higher after announcing that the FDA accepted the New Drug Application ("NDA") resubmission for Tlando (testosterone undecanoate), a potential rival for Jatenzo from Clarus Therapeutics (NASDAQ:CRXT). The federal agency has designated the marketing applicati...

LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO® PDUFA target action date set for March 28, 2022 PR Newswire SALT LAKE CITY , Feb. 3, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceuti...

Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO® PR Newswire SALT LAKE CITY , Jan. 27, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine d...

Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference PR Newswire SALT LAKE CITY , Jan. 5, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announ...

Lipocine (NASDAQ:LPCN) announces that the first patient has been dosed in its Phase 2 proof-of-concept clinical study for the management of liver cirrhosis. Shares down 2.8% premarket at $1.06. The primary endpoint is change from baseline in Skeletal Muscle Index via computed tomogr...

LIPOCINE ANNOUNCES PATIENT DOSED IN ITS PHASE 2 STUDY WITH LPCN 1148 FOR MANAGEMENT OF LIVER CIRRHOSIS PR Newswire SALT LAKE CITY , Dec. 22, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic an...